Beta Drugs Ltd.
| BSE: 535022 | Sector: Health care |
| NSE: BETA | ISIN Code: INE351Y01019 |
| BSE 05:30 | 01 Jan | Beta Drugs Ltd |
| NSE 13:19 | 18 May | 858.70 |
-18.00 (-2.05%) |
OPEN
870.00 |
HIGH
871.00 |
LOW
858.70 |
| OPEN | |
| PREVIOUS CLOSE | |
| VOLUME | |
| 52-Week high | 0.00 |
| 52-Week low | 0.00 |
| P/E | |
| Mkt Cap.(Rs cr) | 0 |
| Buy Price | |
| Buy Qty | |
| Sell Price | |
| Sell Qty |
Beta Drugs Ltd. (BETA) - News Sector
-
Dr Lal Pathlabs slips 6%, hits 52-week low post muted Q4 results
9.52 am | 18 May 2022 | Business Standard
In Q4FY22, normalised earnings before interest, taxes, depreciation, and amortization (EBITDA) margins contracted 630 bps to 19.4 per cent from 25.7 p...
-
Dr Lal Pathlabs Q4 consolidated PAT dips 27% to Rs 62 cr, stock sheds 1%
1.47 am | 18 May 2022 | Business Standard
Operating revenue rose 12.7% during the quarter to Rs 485.5 cr; Covid-19 and allied segments added roughly 13.6% to Q4 top line
-
Aurobindo hits 2-year low; dips 11% in a week on USFDA's 6 observations
12.42 pm | 17 May 2022 | Business Standard
Analysts at ICICI Securities expect Aurobindo Pharma's adjusted PAT to de-grow 30.4 per cent year-on-year (YoY) to Rs 557.90 crore in the March 2022 q...
-
GlaxoSmithKline Pharma reports consolidated net loss of Rs 55 crore
1.05 am | 17 May 2022 | Press Trust of India
Revenue from operations rose to Rs 810 crore for the fourth quarter, compared with Rs 744 crore in the year-ago period, the pharmaceutical major said ...
-
USFDA rush after 2-year lull: 20-30% new products may be open to inspection
3.01 am | 16 May 2022 | Business Standard
The last two years saw limited physical inspections due to travel restrictions during the pandemic
-
A first in India: Zydus brings new drug for uncontrolled 'bad' cholesterol
12.04 am | 14 May 2022 | Business Standard
Uncontrolled LDL-c, which poses a major risk of cardiovascular diseases, lacked proper treatment despite patients' lifestyle changes and use of statin...
-
Cipla looks to invest more in mRNA tech; holds discussions with firms
2.03 am | 12 May 2022 | Business Standard
Speaking to Business Standard, Samina Hamied, executive vice chairperson, Cipla, says one must invest in research and development (R&D) to feed the co...
-
Cipla will use Covid-19 bulk drugs inventory when demand rises
11.46 pm | 11 May 2022 | Business Standard
The Covid-19 portfolio contributed 5-6 per cent of Cipla's turnover during peak Covid waves, the firm said
-
Bonus issue fails to lift Ajanta Pharma; stock hits 52-week low on weak Q4
12.27 pm | 11 May 2022 | Business Standard
In Q4FY22, Ajanta's earnings before interest, taxes, depreciation, and amortization declined 20 per cent year-on- year to Rs 207 crore.
-
Stocks to Watch: SBI, Cipla, Voda Idea, Gujarat Gas, Zensar, MGL, Welspun
8.11 am | 11 May 2022 | Business Standard
Stocks to Watch Today: The primary market too is likely to be abuzz with activity with three IPOs namely - Delhivery, Prudent Corporate Advisory Servi...
-
Cipla Q4 PAT dips 12% to Rs 362 cr owing to Covid inventory impact
2.26 am | 11 May 2022 | Business Standard
For the full fiscal, Cipla has posted a 4.7% jump in net profit to Rs 2,517 crore, revenue and Ebitda rose 13.6% and 6.4% respectively
-
Sun Pharma's Halol unit gets 10 observations under USFDA's Form 483
1.22 am | 11 May 2022 | Business Standard
Plant's OAI status is unchanged, hinting at status quo; Sun Pharma says will respond to observations within 15 days
-
Rainbow Medicare slumps 17% on debut in worst IPO listing in CY22 so far
11.10 pm | 10 May 2022 | Business Standard
Stock end at Rs 450, Rs 92 below issue price of Rs 542 a share
-
Rainbow Children's Medicare lists at 7% discount to issue price
10.30 am | 10 May 2022 | Business Standard
The stock listed at Rs 506, a 7% discount when compared with its issue price of Rs 542 per share on the BSE.
-
75% of Nifty50 stocks trade below 200-DMA; look weak on the charts
11.43 pm | 6 May 2022 | Business Standard
Tech Mahindra and Wipro have tumbled over 30 per cent, while Apollo Hospitals Enterprise and Dr. Reddy's Laboratories have plummeted 22 per cent so fa...
-
Sanofi India: Strong balance sheet, high cash reserves positives for stock
12.29 am | 6 May 2022 | Business Standard
Products in the price control list and growth of the non-power brand portfolio will be key monitorables
-
Pfizer sets up drug development centre at Chennai's IIT Research Park
9.34 am | 5 May 2022 | Business Standard
The centre integrates two essential functions under the export-oriented undertaking of Pfizer: Pharmaceutical Sciences (PharmSci) and Global Technolog...
-
Zomato, L&T Infotech, Solara, TTML plunge over 25% in one month
11.47 am | 4 May 2022 | Business Standard
Shares of Zomato hit a new low of Rs 64.70, down 7 per cent on the BSE in Wednesday's intra-day trade
-
Alembic Pharma posts Q4 net of Rs 35 cr as India and US businesses grow
7.02 pm | 2 May 2022 | Business Standard
During the quarter, Alembic Pharma's US portfolio strengthened with the acquisition of the balance 40 per cent stake in Aleor Dermaceuticals
-
Solara Active Pharma slips 15% after Rajender Rao resigns as MD & CEO
11.21 am | 2 May 2022 | Business Standard
Jitesh Devendra, former CEO and Managing Director (MD) of the company will return to Solara as MD, to steer the reset strategy of the Company
Quick Links for Beta Drugs:
-
News
Announcements Brokerage Reports Business Earnings Sector -
Corporate Action
AGM Board Meetings Bonus Dividends EGM Rights Split -
INFORMATION
Bulk Deals Company History MF Holding Listing Info Locations Shareholding -
Financials
Financial Overview Balance Sheet Profit & Loss Cash Flow Ratios Quarterly Results Half Yearly Results Nine Monthly Results Yearly Results -
Annual Report
Auditors Report Chairman's Speech Company Management Directors' Report Finished Goods Raw Materials -
Peer Comparison
Competition Market Cap Price Price Performance Net Sales Net Profit Total Assets Historical Prices
